Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Degree of Tissue Differentiation Dictates Susceptibility to BRAF-driven Colorectal Cancer

ABSTRACT: Degree of Tissue Differentiation Dictates Susceptibility to BRAF-driven Colorectal Cancer

PROVIDER: PRJNA416320 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6234910.fastq.gz	Fastqsanger.gz
	SRR6234911.fastq.gz	Fastqsanger.gz
	SRR6234912.fastq.gz	Fastqsanger.gz
	SRR6234913.fastq.gz	Fastqsanger.gz
	SRR6234906.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Degree of Tissue Differentiation Dictates Susceptibility to BRAF-driven Colorectal Cancer

Project description:In murine models, we find that oncogenic BRAF paradoxically suppresses stem cell renewal and instead promotes differentiation and senescence. This corresponds to inefficient tumor formation in oncogenic BRAF mouse models of colon cancer. By reducing levels of differentiation in the gut via genetic manipulation of either of two distinct differentiation-promoting factors (Smad4 or Cdx2), stem cell activity is restored in BRAFV600E intestines, and the oncogenic capacity of mutant BRAF is amplified. In human patients, we observe that reduced levels of differentiation in normal tissue is associated with increased susceptibility to serrated colon tumors. Together, these findings help resolve the conditions necessary for BRAF-driven colon cancer initiation.

2017-12-26 | GSE106330 | GEO

Degree of Tissue Differentiation Dictates Susceptibility to BRAF-Driven Colorectal Cancer.

Project description:Oncogenic mutations in BRAF are believed to initiate serrated colorectal cancers; however, the mechanisms of BRAF-driven colon cancer are unclear. We find that oncogenic BRAF paradoxically suppresses stem cell renewal and instead promotes differentiation. Correspondingly, tumor formation is inefficient in BRAF-driven mouse models of colon cancer. By reducing levels of differentiation via genetic manipulation of either of two distinct differentiation-promoting factors (Smad4 or Cdx2), stem cell activity is restored in BRAFV600E intestines, and the oncogenic capacity of BRAFV600E is amplified. In human patients, we observe that reduced levels of differentiation in normal tissue is associated with increased susceptibility to serrated colon tumors. Together, these findings help resolve the conditions necessary for BRAF-driven colon cancer initiation. Additionally, our results predict that genetic and/or environmental factors that reduce tissue differentiation will increase susceptibility to serrated colon cancer. These findings offer an opportunity to identify susceptible individuals by assessing their tissue-differentiation status.

| S-EPMC5747303 | biostudies-literature

UV-induced DNA lesion mapping reveals that carcinogen susceptibility is regulated by genome architecture and dictates cancer mutagenesis

Project description:In this study, we present the first quantitative human genome-wide map of DNA lesions induced by ultraviolet (UV) radiation, the ubiquitous carcinogen in sunlight that causes skin cancer. Remarkably, the pattern of carcinogen susceptibility across the genome of primary cells significantly reflects mutation frequency in malignant melanoma. Surprisingly, DNase-accessible euchromatin is protected from UV, while lamina-associated heterochromatin at the nuclear periphery is vulnerable. Many cancer driver genes have an intrinsic increase in carcinogen susceptibility, including the BRAF oncogene that has the highest mutation frequency in melanoma. These findings provide a genome-wide snapshot of DNA injuries in cells at the earliest stage of carcinogenesis. Furthermore, they identify carcinogen susceptibility as a previously unrecognized origin of mutagenesis that is regulated by nuclear architecture and dictates genome instability in cancer.

2017-08-12 | GSE94434 | GEO

microRNA expression profile between KRAS/BRAF wild and BRAF mutant colorectal cancer

Project description:The genome-wide miRNA expression analysis was performed in clinical samples, comprising 15 BRAF-mutant and 15 non-KRAS/BRAF-mutant colorectal cancers by using a SurePrint G3 Human miRNA microarray. clinical samples, comprising 15 BRAF-mutant and 15 non-KRAS/BRAF-mutant colorectal cancers by using a SurePrint G3 Human miRNA microarray.

2016-04-01 | E-GEOD-66548 | biostudies-arrayexpress

microRNA expression profile between KRAS/BRAF wild and BRAF mutant colorectal cancer

2016-04-01 | GSE66548 | GEO

Targeting MUC1-C sensitizes colorectal cancer cells to BRAF inhibitor

Project description:BRAF mutant colorectal cancer has a poor prognosis and gets resistant to BRAF inhibitors quickly. This study aims to clarify the mechanism of resistance to BRAFi. We found MCU1-C is overexpressed in BRAF mutant colorectal cancer and targeting MUC1-C genetically and pharmacologically sensitized Colorectal cancer cells to BRAF inhibitor. This finding suggests that MUC1-C could be a new therapeutic target for BRAF mutant colorectal cancer.

2022-11-30 | GSE215849 | GEO

HDX-MS data on bRaf, bRaf/Cdc37 and bRaf/Cdc37/Hsp90 protein complexes

Project description:HDX-MS data on bRaf, bRaf/Cdc37 and bRaf/Cdc37/Hsp90 protein complexes

2022-01-04 | MSV000088635 | MassIVE

Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers

Project description:Analysis of BRAF variant gene expression activity after constitutive variant expression in immortalized lung ephithelial cells. The hypothesis tested in the present study was that the level of BRAF activity will vary based on the identity of the variant expressed. Results provide important information on the variation and continous quality of BRAF activity across diverse variants that were tested.

2019-10-06 | GSE133151 | GEO

Understanding the mechanisms of resistance to BRAF inhibitors in colorectal cancer

Project description:Mutations in proto-oncogene BRAF occur in about 10-15% of CRC patients and BRAFV600E is the most common. Most patients with BRAFV600E metastatic CRC show reduced survival compared to patients with wild-type BRAF. For patients who undergo BRAF-targeted therapy, resistance develops 4-6 months after treatment initiation and results in more aggressive disease. We established PT130 cells resistant to PLX8394, a novel BRAF inhibotor, and tested them in vitro and in vivo.

2025-09-01 | GSE248414 | GEO

BRAF paradox breakers PLX8394 and PLX7904 comparison to BRAF inhibitor PLX4720 effect on BRAF V600Ε mutant colorectal adenocarcinoma cells

Project description:Genomic analysis on RKO cells treated with PLX7904, PLX8394 and PLX4720 to reveal gene expression patterns. The goal is to investigate the potential of the novel BRAF inhibitors-paradox breakers to impede colorectal cancer cells proliferation, using human cell lines bearing the BRAFV600E mutation.

2021-01-14 | E-MTAB-9014 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data